- Home
- UNH vs NVO Comparison
UNH vs NVO Comparison
Compare UNH & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNH
- NVO
- Stock Information
- Founded
- UNH 1977
- NVO 1923
- Country
- UNH United States
- NVO Denmark
- Employees
- UNH N/A
- NVO N/A
- Industry
- UNH Medical Specialities
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNH Health Care
- NVO Health Care
- Exchange
- UNH Nasdaq
- NVO Nasdaq
- Market Cap
- UNH 279.9B
- NVO 278.0B
- IPO Year
- UNH 1984
- NVO N/A
- Fundamental
- Price
- UNH $281.08
- NVO $71.72
- Analyst Decision
- UNH Buy
- NVO Buy
- Analyst Count
- UNH 24
- NVO 3
- Target Price
- UNH $424.52
- NVO $112.00
- AVG Volume (30 Days)
- UNH 13.2M
- NVO 7.5M
- Earning Date
- UNH 07-29-2025
- NVO 08-06-2025
- Dividend Yield
- UNH 3.15%
- NVO 1.65%
- EPS Growth
- UNH 44.67
- NVO 17.93
- EPS
- UNH 23.82
- NVO 3.40
- Revenue
- UNH $410,057,000,000.00
- NVO $43,922,211,349.00
- Revenue This Year
- UNH $13.42
- NVO $18.59
- Revenue Next Year
- UNH $6.38
- NVO $15.61
- P/E Ratio
- UNH $11.80
- NVO $20.82
- Revenue Growth
- UNH 8.06
- NVO 24.11
- 52 Week Low
- UNH $248.88
- NVO $57.00
- 52 Week High
- UNH $630.73
- NVO $139.74
- Technical
- Relative Strength Index (RSI)
- UNH 37.44
- NVO 57.75
- Support Level
- UNH $278.22
- NVO $64.12
- Resistance Level
- UNH $292.64
- NVO $71.75
- Average True Range (ATR)
- UNH 6.82
- NVO 1.52
- MACD
- UNH -0.68
- NVO 0.44
- Stochastic Oscillator
- UNH 9.51
- NVO 99.02
About UNH UnitedHealth Group
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.